Pharma services M&A panel discusses K-shaped market, AI disruption, and reshoring realities in Q4 2026
Summary
Host Raman Sehgal interviews Sami Hawwa, Sabina Ouimet-Storrs, and James West about the pharma services M&A landscape. The panel describes a 'K-shaped' market where specialized manufacturing assets command premium valuations while generalists face pricing pressure. They highlight the impact of AI on deal flow, noting efficiency gains but also underwriting risks. Reshoring trends are discussed, with speakers noting that political drivers are secondary to economic and regulatory realities. The group expresses optimism for 2027, predicting valuation increases and continued consolidation.
Key takeaways
- 1 the I suppose the I'm gonna kind of r roll several things into one here, but obviously the administration in the US, the policy changes, the tariffs, etc., and what's what that has mean for the investment into US manufacturing. And there was a lot of conversation. I think the the figure that um was put out from from the guys at LEK Consulting was like, hey, the five hundred billion dollars of of manufacturing, infrastructure, and pharma is going to be spent and committed in the next few years. The guys effectively said, hey, there's like maybe 15% of this has actually been uh committed and a lot of that was already in in the pipeline.
Unidentified speaker (speaker_0) · 35:56
- 2 resilience around everyone's supply chain. I think people saw the effects of this in COVID. People are seeing the effects of it as well via tariffs. But I think people really want to avoid having that single supplier risk. They're looking for dependable quality and continuity continually. continuity of supply. And that I think will lead to people still making sure that they have enough capacity in the right geographies. And I don't think that will necessarily go away even if tariffs do.
Unidentified speaker (speaker_3) · 37:44
Episode sections
- 0:09 – 9:39
Introduction and Guest Backgrounds
Host Raman Sehgal introduces the episode and guests Sami Hawwa (NewVale Capital), Sabina Ouimet-Storrs (GHO Capital Partners), and James West (Bourne Partners). He provides professional backgrounds for each guest, noting NewVale's focus on pharma services growth equity, GHO's healthcare PE focus and recent merger with CBC Group, and Bourne Partners' role as a mid-market investment bank.
- 9:39 – 13:11
Miscalculated Assumptions on Sector Recovery
Sami Hawwa admits he underestimated the divergence in the pharma services market, expecting a broad recovery tied to biotech funding improvements. Instead, he observed that commercial manufacturing and specialized capabilities remained resilient while other segments faced pricing pressure and excess capacity.
- 13:11 – 15:45
Impact of AI and Customer Behavior Changes
Sabina Ouimet-Storrs discusses how tough years have changed customer outsourcing strategies and highlights the impact of AI, citing an Anthropic article about a one-person biotech using Claude to manage logistics and experiments across 11 labs, completing an antibody proof-of-principle in 18 months.
- 15:45 – 18:30
Macroeconomic Headwinds and Biotech Funding
James West notes that while biotech funding is up, it is concentrated in later stages, creating a divergence between winners and those waiting for recovery. He expresses optimism about a 'biotech spring' but warns of unexpected macroeconomic headwinds, including potential interest rate hikes.
- 18:30 – 23:57
Valuation Gaps and Creative Deal Structuring
The panel discusses the persistent bid-ask valuation gap. James West describes a 'K-shaped' M&A economy where premium assets command high valuations while others struggle. Sabina and James note increased use of earnouts, deferred payments, and stock compensation to bridge valuation differences.
- 23:57 – 33:10
Investment Thesis and Due Diligence
Sami Hawwa explains NewVale's focus on identifying durable tailwinds and resetting founder expectations regarding capital requirements for value inflection points. Sabina Ouimet-Storrs highlights increased diligence on the buy side and interest in complex formulation capabilities and Asian R&D trends.
- 33:10 – 35:17
Market Segments: Overcapitalization vs. Specialization
Speaker_2 notes that while some areas like cell and gene therapy supply chains and medical communications have faced challenges due to overcapitalization or technology shifts, specialized capabilities in critical drug development steps remain resilient. Niche players in branded generics also outperform broader players.
- 35:17 – 42:43
Tariffs, Reshoring, and Manufacturing Investment Reality
The host cites LEK Consulting data suggesting only 15% of the $500 billion in announced US pharma manufacturing investment has been committed. Speaker_3 argues that supply chain resilience, driven by lessons from COVID and tariffs, will sustain reshoring even if tariffs disappear. Speaker_1 adds that onshoring is real but constrained by economics and regulatory risk, noting Europe remains a powerhouse.
- 42:43 – 49:59
AI Impact on Deal Flow and Valuation
Speaker_2 describes a 'heat map' where people-based consultancies face pricing pressure from AI, while strategic advisors with deep institutional knowledge see heightened demand. Speaker_3 states they are conservative on AI upside due to underwriting difficulties and computational costs, avoiding assets with significant unquantifiable AI downside risk. Speaker_1 notes a flipped burden of proof for software companies regarding AI disruption.
- 49:59 – 59:43
Lightning Round: Market Outlook and Trends
All three speakers predict valuations will be up in the next 12 months. Regarding deal structure, two prefer bolt-ons while one prefers platform deals. On geography, two favor US manufacturing while one favors Asia diversification. For attractive subsectors, speakers mention peptides, accelerating clinical development, and manufacturing enabling technologies. All express optimism for 2027.
Claims worth verifying
NewVale Capital has five investments in its first fund, with four in the manufacturing ecosystem.
Unidentified speaker (UNKNOWN) ·10:31
How to verify: NewVale Capital investor relations page or press releases regarding their first fund portfolio composition. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Argonaut is a California-based fill finish CDMO.
Unidentified speaker (speaker_1) ·10:51
How to verify: Argonaut corporate website or SEC filings if publicly traded; company press releases. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceNoxalizer is a terminal sterilization platform.
Unidentified speaker (speaker_1) ·10:51
How to verify: Noxalizer corporate website or press releases. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Azon is a GXP software company.
Unidentified speaker (speaker_1) ·11:03
How to verify: Azon corporate website or press releases. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
CAI is a CQV platform helping with commissioning and validating manufacturing sites.
Unidentified speaker (speaker_1) ·11:03
How to verify: CAI corporate website or press releases. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
GHO Capital Partners announced a combination with CBC Group.
Unidentified speaker (speaker_3) ·8:58
How to verify: GHO Capital Partners press releases or news articles from late 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceCBC Group is Asia's largest healthcare private equity firm.
Unidentified speaker (speaker_3) ·8:58
How to verify: CBC Group corporate website or industry reports on PE firms in Asia. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceSabina Ouimet-Storrs led successful exits from DDC and Caprion at GHO.
Unidentified speaker (speaker_0) ·3:18
How to verify: GHO Capital Partners press releases or news articles regarding these exits. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceSabina Ouimet-Storrs serves on the board at Ardena.
Unidentified speaker (speaker_0) ·3:18
How to verify: Ardena corporate website board of directors page or SEC filings if publicly traded. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Primary sourceSabina Ouimet-Storrs began her career at PWC before moving to Fulcrum Capital in Toronto.
Unidentified speaker (speaker_0) ·3:47
How to verify: Sabina Ouimet-Storrs LinkedIn profile or professional biography on GHO Capital Partners website. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
LEK Consulting stated that $500 billion of manufacturing infrastructure and pharma investment is going to be spent and committed in the next few years, but only about 15% has been committed.
Unidentified speaker (speaker_0) ·35:56
How to verify: Search for LEK Consulting reports or press releases from 2026-08-20 to 2026-11-20 regarding US pharma manufacturing investment figures. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Cell and gene therapy supply chain capacity needs have been less than expected, leading to overcapitalization.
Unidentified speaker (speaker_2) ·34:12
How to verify: Review industry reports on cell and gene therapy manufacturing capacity utilization from 2026-08-20 to 2026-11-20. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
NewVale Capital has invested in Argonaut and CAI.
Unidentified speaker (speaker_1) ·39:30
How to verify: Check NewVale Capital's portfolio page or press releases for investments in Argonaut and CAI. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Europe runs a huge trade surplus with the US for pharmaceutical products.
Unidentified speaker (UNKNOWN) ·41:11
How to verify: Consult US Census Bureau or European Commission trade data for pharmaceutical products for the period 2026-08-20 to 2026-11-20. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Valuations are expected to be up in the next 12 months.
Unidentified speaker (speaker_3) ·50:34
How to verify: This is a forward-looking opinion; verify by tracking M&A transaction multiples in the pharma services sector over the next 12 months. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Peptides are the most attractive pharma services subsector for 2027.
Unidentified speaker (speaker_3) ·51:31
How to verify: Monitor investment activity and M&A deals in the peptides sector in 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Accelerating clinical development is the most attractive segment.
Unidentified speaker (UNKNOWN) ·51:38
How to verify: Monitor investment activity in clinical development acceleration services in 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Manufacturing enabling technologies, automation, validation, and AI in manufacturing are the most attractive segments.
Unidentified speaker (speaker_1) ·51:56
How to verify: Monitor investment activity in manufacturing enabling technologies in 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.
Do your own research
- Verify NewVale Capital's portfolio company details via SEC Form D filings or company press releases.
- Check LEK Consulting's 'Pharma Manufacturing Outlook' report for the $500 billion investment commitment data.
- Review Anthropic's blog or technical reports for the specific case study on the one-person biotech using Claude.
- Analyze FDA IND application statistics from Asia vs. US/EU using FDA annual reports or IQVIA data.
- Assess current interest rate forecasts from the CME FedWatch Tool against the speakers' 'rate hike' claims.
- Evaluate the 'K-shaped' market thesis by comparing valuation multiples of specialized vs. generalist CDMOs using public company filings.
- Check for conflicts of interest: Guests represent investment firms (NewVale, GHO) and an investment bank (Bourne Partners).
- Review the specific terms of recent M&A deals in the pharma services sector to verify the prevalence of earnouts and deferred payments.
Full transcriptexpand
0:09Unidentified speaker (UNKNOWN): Hey
0:09Unidentified speaker (speaker_0): guys and girls, welcome back to Molecule to Market, where we go inside the outsourcing space of pharma services and biopharma services, covering every stage of the global drug development and commercialization lifecycle. I am your host, Roman Tagal, and today's episode I'll be speaking about the pharma and biopharma MA Ego. ecosystem for quarter four 2026. It's a round table, my friends, and these tend to be uh some of the most popular episodes that we ever have on the podcast, particularly the deal making MA space. And my guests today are three of the best people in the sector. And, you know, sometimes I share information on this podcast from the various sources that I meet and speak to in the sector. And three of the get the three guests that I have today are top of that list for where I get my knowledge on what's going on in the sector. So who are those three people? Well first and foremost, I think it's her third time on the podcast is the lovely Sabina Weimar Weimer Stores, who is a principal at GHO Capital Partners. Next up is James West, who is managing director and head of Europe at Bourne Partners. Also a friend of a show, James has been on before. And since then he's moved to Bourne Partners. If you are a regular listener of the podcast, you'll know that Banks,
1:28who is the head of Born Partners, was on the podcast a few months ago. And then a first-time First time interviewee on the podcast, the dashing Sammy Howard, Howitt, who is a managing director and a part of the founding team at Newvale Capital in New York, a business I've got to know really well over the last few years. As he started his own fund uh with some colleagues, and those guys are crushing it and doing it really well, which we get into today.
1:58Unidentified speaker (UNKNOWN): And
1:59Unidentified speaker (speaker_0): honestly, like today's episode covers lots of things, and I tried to get a kind of an overview of like what's going on in the pharma services space, uh, evaluation, processes, attractive segments, how investors are thinking, as well as kind of some bigger things around, for example, tariffs, reassuring AI, and all that kind of stuff. And also just some sentiment for the year ahead. Um, so let me tell you a bit more about my guests before we get into today's show. Um Uh, Sammy Hauer is managing director at Newvale Capital, where he focuses on investments in the services and enabling technologies underpinning the life sciences industry. At Newvale, the investment focus spans the pharma value chain from drug discovery and clinical development through manufacturing and commercialization, just like our podcasts. Uh, and Sammy Sami is actively involved in sourcing and executing new investments and partnering with management. teams to accelerate growth, strengthen operations, and build scalable market leading businesses, which he talks about today. And Sabina Weime Stores, who is a principal at GHO, um, where she co-leads the firm's efforts in the biopharma subsector. She has more than a decade of experience investing in healthcare businesses across Europe and North America. And since joining GHO in 2015, she has partnered with management teams through periods of significant
3:18growth and transformation. She led two successful exits, DDC and Caprion, and currently serves on the board at Ardena.
3:28Unidentified speaker (UNKNOWN): She
3:28Unidentified speaker (speaker_0): worked closely with leadership teams on strategy, value creation, and growth, and particularly values the partnership side of the role. Sabina began her career at PWC before moving. into the PE world at Fulcrum Capital in Toronto. Uh, she holds a Bachelor of Commerce uh from Dalhousie University and is a chartered professional accountant. And outside of work, she is a mom to three young girls who keep her negotiation skills sharp and her ego firmly in check. I can in fact confirm that as I've had the absolute privilege of meeting her three girls. and her partner, and they do just that. They are an absolute treat, but a lot to handle. And last but certainly not least, a good friend of the show and a good friend of mine, Mr. James West. His I mentioned now leads Bourne Partners European business, bringing 15 years of MA experience across pharma services and products. He's worked extensively with PE funds, their portfolio companies and independent entrepreneurs in the sector, and has spent his professional career advising these groups on global MA transactions from both London and New York. And I have to say, uh, one of those independent entrepreneurs was in fact me, because James was my investment banker when I sold uh a portion of my business for marketing to North Edge Capital back in 2022. So, someone I
4:47know particularly well, someone I trust, and uh a great uh contribute. contribution to today's show. As always, thank you, listener, for listening. And please leave us a kind rating wherever you're listening to today's show. But above all, enjoy. This episode is brought to you by Bora Pharmaceuticals. I've got a real soft spot for Bora. I first met Bobby Sheng, the CEO, back in 2017, and it's been amazing to watch the business grow and expand to become truly top-tier. global CDMO. Bobby was in fact one of our first ever guests on Molecule to Market. A great, great guy. Borin now supports many of the biggest pharma companies across the globe. Borin's become known as the CDMO that brings a genuine partnership to clients, shown through their shared risk promise, their white glove service, and their peerless on-time on time infull in full delivery record. If you want to feel more confident about your CDMO, then I suggest you head to Bora CDMO dot com. All right guys, welcome to Molecule to Market. James and Sabina, welcome back first and foremost. And Sammy, what a debut for you. This is exciting to have you on the podcast, my friend. So someone I've gotten to know really well over the last few years and uh I'm grateful that you've decided to join us on this round roundtable. table. So as we start with you, Sammy. Sammy, give our listener a bit of a kind of an
6:06overview of who you are, a bit about Newvale and a bit about your background, and then we'll pass to James and then to Sabinar as well to do the same.
6:14Unidentified speaker (speaker_1): Sure. Yeah, it's great to be here uh with with you all. And it's only taken, I think, three and a half years to finally get invited to the infamous podcast. So I'm Sammy Hower, Howa, uh a managing director at New Vale. Newbell Capital. We're a growth equity firm focused exclusively on pharma services and the technologies that support our industry. Um typically invest between 10 to 50 million dollars of equity into businesses that are really helping pharma companies and life sciences companies develop, manufacture, and then ultimately commercialize their drugs more efficiently. Um really nice to be here and and appreciate you uh having me on.
6:54Unidentified speaker (speaker_0): Great to have you here. I mean, to be honest with you, Sammy, there's a lot of charlatans in the private equity world that come into our sector that hang around and I needed to see what deals you were doing, and you've done some pretty good deals. So finally you've you've reached you've reached the James West bar of excellence, which leads me nicely on to my favorite investment banker in the sector, Mr. James West.
7:14Unidentified speaker (UNKNOWN): Thanks,
7:14Unidentified speaker (speaker_2): Kyle. guys. I appreciate the uh the high bar. Um yeah, so for everyone, my name is James. I'm a managing director at Bourne Partners and I lead our European business. Um I've been advising owners and CEOs forever in pharma services, uh between New York and London. And we're having a lot of fun at Bourne Partners. We're building and scaling our business and yeah. I mean to be the global preeminent mid market investment bank. So yeah, looking forward to today.
7:45Unidentified speaker (UNKNOWN): And
7:45Unidentified speaker (speaker_0): I think the last time you were on James might have been before you joined Bourne. And uh I'd certainly for anyone that's looking for background on the the firm that James works for there we did a we did a great episode with Banks, who is uh the the founder of Bourne Born, and uh I certainly encourage people to go back and listen to that episode, which was excellent to kind of get a bit of background. So great to have you here, James. And last but certainly not least, your friend and mine, Sabina.
8:13Unidentified speaker (speaker_3): Thank you. Great to be back. This is uh this is actually the third time I'm on the podcast. So I'm honored. Um so for for those that don't know me, I'm Sabina. I'm uh a principal at at GHO, uh, which is a healthcare focused private equity firm. Uh we do a lot of similar stuff to uh what Sammy's firm does, um slightly larger tickets, though, and we also
8:38Unidentified speaker (UNKNOWN): look
8:38Unidentified speaker (speaker_3): at other parts of the healthcare market, including um health tech, medtech, and life science tools and diagnostics. Um, but obviously we do a lot of pharma services as well. So very relevant uh to the podcast. And I think since the last time I was on the podcast, we've also announced that we're combining with uh CBC Group, which is Asia's largest healthcare private equity firm. So we will be the uh largest global healthcare firm very soon. And I think very relevant to some of the things we're going to be discussing today. So looking forward to it.
9:13Unidentified speaker (speaker_0): Very good to know. I may have come completely missed that, Sabina, because I did not know that. But that's uh breaking news here on Molecules.
9:20Unidentified speaker (UNKNOWN): There you
9:20Unidentified speaker (speaker_0): go. If you've completely missed it like me. Um all right. Like so normally when we do these roundtables, especially at this time of year, like off the back of CPHI and C DMO uh live in in the US and some of the big clinical research events, we've got a sense of like how the year has been and what our kind of eyes are are on the year ahead. But I kind of want to start with looking back over the last 12 months and maybe thinking about whether were there any assumptions that around pharma services and investing in pharma services that that you got wrong or that you kind of miscalculated. And I appreciate I'm asking you guys to kind of own up to things that you may have just not seen on the horizon. Uh but don't worry I'll get to your strong points at some point in the discussion. as well. So, um, Sammy, why don't we start with you? Obviously you guys um have done and maybe maybe actually I won I won't mention this, but maybe give a context to some of the investments that you guys have done in the last couple of years and and then talk about, you know, generally the last twelve months for for Newvale.
10:19Unidentified speaker (speaker_1): Yeah. Yeah, happy to. Um we uh we typically don't admit when we get things wrong, but for you Roman, Rahman, since it's my first time on the podcast, I will. Uh so you know, I think for us, we have
10:31Unidentified speaker (UNKNOWN): we
10:31Unidentified speaker (speaker_1): have five investments in our first fund. Four of those five sit within the manufacturing ecosystem. And it it's everything from specialized uh manufacturing platforms like Argonaut, which is a uh California-based fill finish C DMO, to Noxalizer, which is a terminal sterilization. platform, to GXP software like Azon, and CAI, which is a CQV platform helping with commissioning and validating manufacturing sites. All of those were a result of kind of thematic work that we have had in this space and play across tailwinds that we feel like are extremely durable. given um a very kind of broad use case and underlying demand for each of those services. So nothing I told you is a very specialized modality where, you know, one bad clinical trial could ultimately shape the way that those um those service providers would would would react. You know, I think looking back twelve 12 months, one thing, you know, we and and I probably got wrong is just how different various parts
11:43of the pharmaceuticosystem have performed. You know, I would have expected, just given how XBI has performed, how MA funding uh to to biotech has performed, a more kind of broad based recovery across the sector, especially again as that biotech funding started to improve and some of the uncertainty around environmental uh changes and regulatory changes have evolved. But I think what we've seen is a significant divergence where certain parts of the market are still struggling with slower demand, some of the pricing pressure and excess capacity, while other areas, especially those tied to commercial manufacturing, some of the onshoring that we'll talk about, um, and specialized. kind of capabilities have probably remained extremely resilient.
12:31Unidentified speaker (speaker_0): That's great to hear. And uh certainly I thought your point there around expecting a broad-based recovery. Um, I I'm probably the same, right? I think uh, you know, the biotech funding piece uh has certainly recovered, and I would have expected that across multiple segments. But you know, given you guys have investments in different parts of the ecosystem, you guys get to see it firsthand. So thank you for that. And and Sabina, maybe you mentioned you guys obviously work across a larger kind of um kind of ticket size. And so, how do you guys look at the last 12 months, both in terms of general reflections and any assumptions that you maybe got wrong around uh around pharma services generally?
13:11Unidentified speaker (speaker_3): So, look, I think a a lot of what um Samuel Sammy says resonates with with what we've seen over the last twelve months. I think we've all been waiting for that biotech recovery to flow through. And I think we're starting to see some green shoots there. And that obviously takes a while to trickle through the system and to kind of hit a lot of our C DMOs and and other pharma services businesses. I think what we may have um not necessarily gotten wrong, because we don't get much wrong, but maybe in terms of what has surprised us is just thinking about how how these how the tough years has really impacted um a lot of the customers, right? So how how they think about outsourcing, um, you know, what are they gonna buy? Who are they gonna partner with? They're gonna think about, you know, trimming down potentially the the people that they do want to partner with, how they're gonna pay for it. And so how is that um, you know, what's the operating model um gonna be like? And so how we interact with our customers is obviously
14:20something that we're that our company's customers are adapting to. And then also I think we're we're starting to see the impacts of of AI. And I don't know if you guys um read the super interesting anthropic article that came out this week. Um but there was an example where you have you know one a one person biotech essentially using Claude um to run you know logistics and contracts um and experiments across 11 external labs and taking an antibody essentially from an idea to proof of principle in 18 months. And that's you know, that's quite remarkable. So thinking about how how that's going to develop and how that's going to impact you know, our ecosystem and and particularly you know, our C DMOs, you know, things are going to gonna hopefully start. to flow through a bit faster. And so thinking thinking about um all of those aspects when the recovery comes, because I think it is coming, um, is gonna be really exciting for things to to watch out for for twenty seven.
15:28Unidentified speaker (speaker_0): Very good. And I need to get that person, that gal or guy on the podcast, because 'Cause that sounds absolutely uh amazing. And thanks for that, Sabina. James, you you obviously part of your job as investment banker is to tell everyone how fantastic the sector is because then you can get some deals done. So how do you
15:45Unidentified speaker (UNKNOWN): fr
15:45Unidentified speaker (speaker_0): like firstly from your like your perspective, how has the how has the reality been in twenty twenty six versus maybe how you were expecting or maybe sharing with your clients what the reality was going to be in twenty 2026. twenty six?
15:59Unidentified speaker (speaker_2): Yeah, I see it the same way. I think of myself as the forever optimist. uh in MA. Um you you're right. We all I think everyone thought MA volume generally would be higher in the mid market this year. Um we've seen some just I think it's just been mentioned about biotech funding's been up, but we've seen much more concentrated fundraising rounds and much later stage. So that has created a bit more of a divergence between winners and people who are still waiting for the recovery to hit.
16:30Unidentified speaker (UNKNOWN): Now,
16:30Unidentified speaker (speaker_2): in true James West style, I remain an optimist. I describe the uh the biotech funding cycle as the I believe we're out of the biotech winter and we're in the biotech spring. And the the shoots are coming. It just takes time for all that funding to come through into the service sector, into the clinical trials, into the manufacturing. in in any sort of scale. So we thought there'd be more MA. It will come. Cycles do come around. Um I think the thing we couldn't predict was more macroeconomic headwinds this year. I think everyone expected interest rates and everything to be going going down across all major economies. And it looks like that's maybe getting rate hikes now in the next six to twelve months. That does impact a bit of the economic economics of investing. Um but I don't think that will slow down, you know, just better quality, more volume for MA in the mid market next year.
17:24Unidentified speaker (speaker_0): Just a quick follow-up on your piece around biotech funding, are you seeing
17:29Unidentified speaker (UNKNOWN): are
17:29Unidentified speaker (speaker_0): you seeing any behavioral change by biotechs in the way they think about outsourcing? Um I mean to to Sabina's example there, you know, that that guy is presumably outsourcing absolutely everything, which is kind of the classic virtual biotech model. We've seen, for example, a lot of in-housing going on at big pharma companies. So I'm just curious, James, have you seen any kind of sense of biotechs investing to do stuff themselves? Or actually is the the cost of capital and all the uncertainty Driving them to continue to outsource and maybe more so than than previous to COVID even.
18:03Unidentified speaker (speaker_2): Yeah, we're still seeing that the outsourcing drive being really strong. Um and some cases quite sensitive to to pricing and cost as well when you're in those early phases. So yeah, we're still seeing that.
18:14Unidentified speaker (speaker_0): I'm gonna stay with you, James, uh, because my next question was around valuations and uh Sabina might recall the last time we did like an MA review like this at the back end of last year, we I think it was the year of era the failed process, and you had this
18:30Unidentified speaker (UNKNOWN): I think we're
18:30Unidentified speaker (speaker_3): still in that era.
18:31Unidentified speaker (speaker_0): Yeah. Well, I don't
18:33Unidentified speaker (UNKNOWN): know.
18:33Unidentified speaker (speaker_0): We're coming
18:34Unidentified speaker (UNKNOWN): to
18:34Unidentified speaker (speaker_0): that. We're coming to that. Um and to me, you might recall, we talked on that particular episode about the gap between say a seller's expectation of valuation versus what the buyer is willing to pay. So particularly in examples where a private equity company may have overpaid in you know in 2021, 2022, or whatever, relative to how the market was then versus how things are today. Um so James, I'll start with you. Are you are you still seeing like a meaningful gap between the the ask amount and in the the actual valuation amount?
19:12Unidentified speaker (speaker_2): Yeah, we are, and it it's advice. a nice second question because a lot of the businesses who've maybe struggled over the last twelve, twenty-four, thirty-six months, um, you know, if they're coming to market without that track record of revenue growth or that profile of business, you know, maybe it's a harder sale. Um and so you do end up with that valuation gap, or it might be that you pause a process or like we spoke about last year, uh maybe unable. And I think that's really that sort of K-shaped MA economy of if you're an A-star business and every box is ticked, there is such a uh amount of demand for those businesses with private equity and other trade buyers that we're still seeing very high valuations businesses being very competitive. But if you're not,
20:01Unidentified speaker (UNKNOWN): you
20:02Unidentified speaker (speaker_2): know, it's sort of slower, it's scrutinized, much more difficult to get a deal done. We're still seeing that um sort of two two lone economy. Um but this year, I mean, anecdotally from our position,
20:14Unidentified speaker (UNKNOWN): we're
20:14Unidentified speaker (speaker_2): seeing that bid R spread and we're seeing more structuring to get around that. So more earnouts, more deferred, more stock compensation versus cash, other ways to to bridge that gap to
20:30Unidentified speaker (speaker_0): Yeah, it's it's a great point. And we've heard that actually on a few episodes of private equity people that we've we've interviewed this year where they've had to be more creative with their assets and and their deals. So that's quite a an interesting point there. Uh Sabina, you obviously, you know, w we talked about this last year, but and you and you kind of mentioned there this this this continued gap. How how is life like at a at a private equity company at the minute in our sector where
20:58Unidentified speaker (UNKNOWN): I
20:59Unidentified speaker (speaker_0): suppose where you may have paid a lot for companies you know many years ago, it's difficult to to move them on for all the reasons James said. But also you're going into the market and great businesses naturally get great values, but there are other opportunities out there but seem to be riskier than maybe before. So how do you
21:16Unidentified speaker (UNKNOWN): how
21:16Unidentified speaker (speaker_0): do you juggle all that?
21:18Unidentified speaker (speaker_3): Yeah, so look, I think from a um from a seller perspective, uh I think it's again,
21:29Unidentified speaker (UNKNOWN): you know,
21:29Unidentified speaker (speaker_3): some uh I think a lot of the businesses that, you know, we've we've all invested in over the last few years have faced, you know, some issues in the biotech funding cycle. and many other things, right? But I think it doesn't really change the fact that a lot of these companies are extremely specialized and are really good at what they do. And um there's obviously a price for that. Um, there is high demand for that. And I think um we're starting to get to a place where the market is recovering, these businesses are. are performing well, and people are really keen to get on to that next that next cycle. And especially if you know these are other healthcare investors looking at these assets, they'll understand, you know, the dynamics and see the opportunity to continue going and and you know taking these businesses to the next level. That that is, you know, the industry and that is what we do. I think from a from an acquisition perspective on the buy side, I think it's you know, the last what four years, um
22:37Unidentified speaker (UNKNOWN): I
22:37Unidentified speaker (speaker_3): I think this year we're starting to see a lot more activity and a lot better quality. And I think we as investors are also a lot more um more diligent because we have failed. faced some you know tougher years I think we know exactly what to look for, where, you know, where the pitfalls might be and and how to work around it. And we are having to be a lot more creative in terms of the structures to kind of minimize that that bid ask spread, because that is still, still the case, I think, um in in a number of situations that we've looked at. And it's not necessarily the multiples per se, but it's you
23:18Unidentified speaker (UNKNOWN): know
23:18Unidentified speaker (speaker_3): what's the eBit DA that you're that you're paying off. I'm still seeing a lot of interesting adjustments and and proformas and getting getting to a place where both buyer and and seller can come to an agreement. It's getting better, but it's it's uh it's still uh troppy waters out there.
23:36Unidentified speaker (speaker_0): Great summary. Sami, Sammy, let's come to you So you guys have done quite a lot of deals in the last few years. And so, you know, you're a a very entrepreneurial fund, I would I would say, and it's something you and I have talked about and that I certainly admire about uh New Vale at the the scale you're at, you can you can do deals quickly and and really look for opportunities. So while Well, what do you guys see in firstly in terms of valuation, you know, to the their point, uh James and Sabina. but also I'm just interested,
24:04Unidentified speaker (UNKNOWN): like
24:04Unidentified speaker (speaker_0): when something comes across your desk, Sammy, like what excites you right now? Like what areas of the market you're like, oh my god, like that's this is what we like, this is what we're after.
24:13Unidentified speaker (speaker_1): Yeah. Well, I thought Sabina and and James described the the the bid ask dilemma in a in a very kind of elegant way. I think premium assets are still
24:25Unidentified speaker (UNKNOWN): are
24:25Unidentified speaker (speaker_1): still getting premium valuations. I think assets that have slower growth or are maybe in areas of the market where the durability of that differentiation hasn't been seen or that pull through hasn't been shown throughout the life of the investment. Um, that's where there's there's challenges, especially when you're anchored to higher multiples and higher historical valuation marks.
24:50Unidentified speaker (UNKNOWN): Terms
24:50Unidentified speaker (speaker_1): of areas that we like, I think I I hit a little bit of this earlier,
24:54Unidentified speaker (UNKNOWN): but
24:55Unidentified speaker (speaker_1): just just given the stage at which we invest, which again is a little bit earlier than where um GHO comes in, like we tend to see customer concentration. We tend to see companies that want to change the world with their software or with their or with their technology or on the services side kind of have. um lofty visions of of what they want to build. And we kind of have to reset that that view and really focus on like what is it that they're offering to the market? How durable is that offering to the market? Is there going to be a ton of change management in the software or the technology that they're trying to sell to what is the most risk adverse customers? customer in the world, right? Pharma. And we have to really kind of reset how much capital it takes to get to the value creation inflection point where a strategic buyer or where James can go sell our business and convince the next private equity sponsor that this thing is now validated, it's scaled, and there's not a lot of risk anymore in what. in you're going to be underwriting. And so for us, that's really where we focus. It's trying to find those assets and then getting alignment with the teams, whether that be a founder, a management team, other investors that
26:15came in before us to to kind of bridge that next value inflection point.
26:19Unidentified speaker (speaker_0): Yeah. Quick point. And you you guys, if I look at your portfolio, some of the companies that you mentioned that I know, you know, you've got, you know, kind of sterile manufacturing capabilities, you've got the terminal sterilization, and also you have a you know right on trend an uh an AI business in the manufacturing space. Like I look at your portfolio and what you guys are doing and kind of like not scratch my head to say how did you pick them, but like what what are you guys doing differently, Sammy? That's and I'm sure there are you know lumps and bumps in your portfolio. Like it's not probably all, you know, all going swimmingly well across the board. But certainly from my vantage point, the businesses you guys have invested in during a trickier market time period have been have been really solid. So not to give the game away of your investment thesis, but like how do you how do you pick 'em, right? Like I'm I'm Um I find that one of the
27:11Unidentified speaker (UNKNOWN): like
27:11Unidentified speaker (speaker_0): the hardest things to to do in this sector.
27:14Unidentified speaker (speaker_1): Yeah, it's every firm says this and and I think because we're so specialized in the sector that we invest in, which is pharma services, um, you know, it's it's easy for us to see these these tailwinds, see these trends, but also not get fooled with areas that may seem like tailwinds and trends, but really aren't long-term long term tailwinds or trends. And so we're we're we orient as a firm around the life sciences customer. That's always been the heritage of Newville. And that's where most of us come from is that life sciences ecosystem, whether it be as a therapeutic investor, an operator within pharma or biotech, or or just having kind of been around that ecosystem. And so we really try to orient around the challenges and the pain points of those customers. And then for us, finding the best of breed services or technologies that address those challenges. And oftentimes when we build a theme, um, there may be a challenge like uh, you know, patient recruitment. You know, that's always been a challenge for for CROs and for site networks and for sponsors that are running trials. Um, but
28:23how do we then go find uh an asset that we feel like is backable to New Vale, that we can get the alignment on entry valuation, on on what we what success looks like under a New Vale investment? Then you start to kind of pick away at, you know, what are the actual opportunities that we could invest in. And so we've definitely Definitely spent spend time time in in areas and themes that we would love to make an investment. We just haven't found an asset yet that makes sense. And those could be fun two, fun three, fund four investments down the line.
28:55Unidentified speaker (speaker_0): Great, great perspective. And like I really like what you said there about kind of not being fooled by tailwinds and trends in almost sense that some of this stuff is faddish and it's a moment in time, which I think is is is super smart. Sabina, you you guys obviously play in a similar field, albeit kind of uh bigger deals. From your perspective, are you seeing areas of the kind of market? You said there was things were picking up from a deal perspective. Are there assets in areas of the market that are really attracting attracting a lot of attention right now in other areas that you think might be being overlooked?
29:27Unidentified speaker (speaker_3): I'll be honest, in pharma services, I wouldn't say that there's any part of the market that's really drowning in in capital right now. I think investors are are still a bit picky and and still a bit gun shy. Um but I think you know some of the areas that might be a bit overlooked. Um and especially right now again I'll I'll talk about AI and and all that. I think people are struggling to kind of think about how that's gonna impact um their, you know, their current businesses but also businesses that they're looking at to invest in. I think some of the areas that are a bit less glamorous but are helping solve technical bottlenecks. I know we we've come across a lot of these businesses in C DMOLAN, but businesses with complex uh formulation and advanced um development capabilities. I'm gonna going to do a soft plug for Arden. Ardenna here because Jeremy will kill me if I don't mention it. But I do think, you know, especially as we're going to start hopefully seeing, you know, more recovery,
30:37more programs coming online. And it's the businesses that really have the technical capabilities as well as capacity. But that those are the things I think that investors are really going to start. flocking towards and and feeling, you know, that they can, you know, moor themselves into the ground and not be too kind of swayed with some of the action that's happening in the background. Um, the other thing I'll say as well is, and this also comes back to kind of the theme I mentioned at the beginning of the podcast, which is Asia. Um, I think, you know,
31:12Unidentified speaker (UNKNOWN): I
31:12Unidentified speaker (speaker_3): don't think I think people are really catching. on to the fact that there's a lot of RD coming out of Asia now, like really high quality molecules. I think we saw at least I and D applications, I think, tripled in the last few years. I think that's that's that's real. And I don't think it's going anywhere. And so we are thinking,
31:34Unidentified speaker (UNKNOWN): you
31:35Unidentified speaker (speaker_3): know, how can our Western companies um take advantage of that? How can we partner with them? Um, and then how can we think about opportunities that we could buy business, you know, in the West as well as the East and combine them and how do you how do you make that um that jump and that that transition? Um I think that's definitely an area where a lot of people are gonna be thinking about and and we definitely are.
32:01Unidentified speaker (UNKNOWN): I
32:01Unidentified speaker (speaker_0): just want to say especially a special thanks to the team at Lead Candidates that support Molecule to Market. They really are the go-to uh talent partner for the pharma and biopharma outsourcing space. I should know because I helped co-found that business and they are doing amazing things for CROs and C DMOs in the sector. So for any talent needs, give the guys a shout. And I will come back to the Asia point. I think it's a great point you make. And uh good shout out. for our day in our business, obviously I know very well, having helped
32:29Unidentified speaker (UNKNOWN): create
32:30Unidentified speaker (speaker_0): the name and a identity uh maybe ten years ago. And I certainly encourage uh our listeners to go back and listen to Jeremy, the CEO's uh fantastic uh it was actually one of our most popular episodes, I think, last year. It was episode two hundred and eighty. What a a great guy and a a great interviewee. And actually, interestingly enough, James, I met Jeremy in person for the first time at the Bourne event last year. So I'll come to you just on that beautiful thread there. James, you th you know, you kind of the perspectives there, right? Sabina giving a sense of I I I really appreciate her transparency and that there's a sense of skepticism for investors across pharma services full stop. But Sammy's also talking about, you know, not getting carried away with things that are not really tail or tailwinds and are or trends. They're just, you know, in disguise, so to speak. When you when as you look at the sector, you know, are you seeing you're doing deals all the time, right, across the ecosystem. Are you seeing certain areas of the market that are particularly sexier right now and then maybe others that are like, this is not their time to shine?
33:32Unidentified speaker (speaker_2): Yeah, we we do see that. Um there's certainly been over the last few years uh sort of areas where uh there's been more private equity investments, um, which has maybe led to sort of overcapitalised parts of the market. Um but I completely agree with Sammy and Sabina that there are yeah, in any part who whatever part of the cycle,
33:55Unidentified speaker (UNKNOWN): you know,
33:55Unidentified speaker (speaker_2): if you're a really specialised, unique capability, you know, generally they f they they'll they fare better than others. If you're in on a critical part of drug development or manufacturing.
34:05Unidentified speaker (UNKNOWN): And
34:05Unidentified speaker (speaker_2): that's I think where it goes beyond just a a tailwind or a trend and you know your core part of the the process. So I mean just adding some bits to that. I mean cell engine therapy supply chain for example, generally pretty well documented. Um people expected that to to need a lot more um capacity than how it's turned out.
34:26Unidentified speaker (UNKNOWN): Uh
34:27Unidentified speaker (speaker_2): another area we say very close to medical communications, very much in vogue five years ago. Again, certain parts of that market are performing really well across commo pharma commercialisation more broadly. Others have been quite challenged with uh with the market and the progress of technology.
34:45Unidentified speaker (UNKNOWN): Um
34:46Unidentified speaker (speaker_2): if you look at branded and specialty generics in Europe, again, some really niche players. um, specialist players doing really well, some broader players faring less well.
34:56Unidentified speaker (UNKNOWN): So
34:56Unidentified speaker (speaker_2): I think in it in all areas there's been a a sort of quite a variance between sort of top performers and other others who've been a bit more challenged.
35:04Unidentified speaker (speaker_0): Challenged. Uh you need to look after your dog in the background as well, Jims. That's uh that's important for you. I'm assuming it's your dog or one of your dogs.
35:12Unidentified speaker (UNKNOWN): Not
35:12Unidentified speaker (speaker_3): mine. It's
35:13Unidentified speaker (speaker_1): got a delivery somewhere,
35:14Unidentified speaker (UNKNOWN): yeah. Um
35:17Unidentified speaker (speaker_0): okay, cool. So I'm just gonna just like shift gears slightly. Um and I've just come back from from C DMO Live Americas and one of the big conversation points in the state of the market address was uh relating to the I suppose the I'm gonna kind of r roll several things into one here, but obviously the administration in the US, the policy changes, the tariffs, etc., and what's what that has mean for the investment into US manufacturing. And there was a lot of conversation. I think the the figure that um was put out from from the guys at LEK Consulting was like, hey, the five hundred billion dollars of of manufacturing, infrastructure, and pharma is going to be spent and committed in the next few years. The guys effectively said, hey, there's like maybe 15% of this has actually been uh committed and a lot of that was already in in the pipeline. So there's a lot of kind of uh big investment projects that are due to to happen, which is uh you know maybe driving some of the resuring uh kind of thesis that were we're getting across. So I'm I'm interested, I suppose, uh Sabine, I'm gonna come to you first on this around
36:32Unidentified speaker (UNKNOWN): the
36:33Unidentified speaker (speaker_0): tariffs and the policy pieces have have created a huge level of uncertainty and complication to the sector. Um, you know, if the if tariffs disappeared tomorrow, do you think the resuring thesis would actually survive? Or is this just a moment in time? And and I'm asking that because that was one of the the perspectives uh which was, you know, this is a moment in time. The administration will be different in a few years' t in a few years' time and we might not have to deal with this. But just curious how you're thinking about the reassuring piece.
37:03Unidentified speaker (speaker_3): Yeah. And it it's funny, I was actually gonna ask you how much of the the committed capital has actually been um been spent. And I think there's a lot of uh people saying that they will be building um and and haven't actually you know struck struck ground. So it I think that's that's an interesting thing and and one to watch. But I do think you know if tariffs disappeared I do think that there was still be an element of of people wanting to have kind of the US for US, Europe for Europe, um, you know, Asia for Asia element. And I think that comes back not necessarily to tariffs, but really around resilience around everyone's supply chain. I think people saw the effects of this in COVID. People are seeing the effects of it as well via tariffs. But I think people really want to avoid having that single supplier risk. They're looking for dependable quality and continuity continually. continuity of
38:03supply. And that I think will lead to people still making sure that they have enough capacity in the right geographies. And I don't think that will necessarily go away even if tariffs do.
38:16Unidentified speaker (speaker_0): Great perspective. Sammy, what are you seeing from that perspective? How you how are you guys looking across your portfolio or indeed your future asset portfolio, you know, from a reassuring perspective? Are you
38:27Unidentified speaker (UNKNOWN): are
38:27Unidentified speaker (speaker_0): you thinking this is here forever or is this a moment in time?
38:30Unidentified speaker (UNKNOWN): I
38:30Unidentified speaker (speaker_1): think onshoring is real. Um but there's a big difference and Sabina mentioned this around, you know, what's getting announced and what's actually getting built. We've seen hundreds of billions of dollars in announced US pharma investment since 2025, but only a small portion of that is actually tied to clearly identified projects and manufacturing sites. And then the counterpoint is that Europe is also continuing to attract substantial investment to the tune of billions and billions of dollars. And so ultimately the onshore decision for pharma comes down to economics. For both pharma and CMOs, transferring established, validated manufacturers. manufacturing processes is expensive and it carries a ton of regulatory and operational risk. And so political pressure alone isn't just going to justify those decisions. And so from our standpoint, obviously we've we've invested in companies that that benefit from the onshoring of manufacturing facilities, such as Argonaut and CA. CAI.
39:40But I think playing the capacity game is going to be really difficult. And building manufacturing capacity based on where you think demand will be in five years is like trying to bet on my Cleveland Browns on a Sunday. I think the bigger opportunity, in our view, is making both existing and new manufacturing capacity more efficient. And how do you actually drive efficiency and not just the new sites that are getting built, which are all highly automated, but also ensuring that sites that need to get redesigned to drive better efficiency, how do you do that and try and minimize the risk that's associated with any sort of tech transfer of a product or a process?
40:22Unidentified speaker (UNKNOWN): Great
40:22Unidentified speaker (speaker_0): perspective. And James, you, if I remember correctly, your current job. title is head of Europe. So you presumably have a very European perspective. I know you work globally, but how you know across the deals that you've done this year and the companies you've engaged with, are you getting a different sense from companies in Europe with respect to resuring and onsuring and whether this is happening you know forever or or is it just happening under the current administration?
40:54Unidentified speaker (speaker_2): Yeah this it's a really topical point. Um I think, yeah, like we mentioned, COVID had everyone thinking about where your supply chains, particularly this year with everything that's going on geopolitically, people are thinking about what are their supply chains, guaranteed security. Um
41:11Unidentified speaker (UNKNOWN): I guess
41:11Unidentified speaker (speaker_2): with Europe and the US in particular, it's with you know Romani Romania and for pharmaceutical products, Europe runs a huge trade surplus with the US and generally for pharmaceutical products.
41:22Unidentified speaker (UNKNOWN): The
41:22Unidentified speaker (speaker_2): US is the largest export market,
41:25Unidentified speaker (UNKNOWN): and
41:26Unidentified speaker (speaker_2): the US is the opposite. The US imports it's a trade deficit for pharmaceutical products. They import a lot, particularly from Europe and other parts of the world.
41:35Unidentified speaker (UNKNOWN): And
41:35Unidentified speaker (speaker_2): that's one of the reasons why pharma's farmers been have in the spotlight because they wanted to address that balance. balance. Now, it's not going to come down to nil in this current administration. I guess there's been a lot of commitments for the current administration in the US. But I I think maybe I share the same view
41:53Unidentified speaker (UNKNOWN): that
41:54Unidentified speaker (speaker_2): generally,
41:55Unidentified speaker (UNKNOWN): you know,
41:55Unidentified speaker (speaker_2): if you're running a specialist manufacturing operation, you know, politics changes, um, particularly in in the West Western Europe and in the US and in a lot of advanced economies. So
42:06Unidentified speaker (UNKNOWN): you
42:07Unidentified speaker (speaker_2): should think about really where's the talent, how can you build your plants, you know, gotta consider all your export markets and how that how that weighs out. Um so we're s we're seeing some
42:18Unidentified speaker (UNKNOWN): sort of
42:18Unidentified speaker (speaker_2): resuring and onsuring, but but ultimately uh from a European perspective, we're a powerhouse in pharma farmer manufacturing, and I think we'll stay that way. particularly for the really advanced, complex
42:29Unidentified speaker (UNKNOWN): uh
42:30Unidentified speaker (speaker_2): manufacturing across the clinical and commercial chain.
42:33Unidentified speaker (speaker_0): Love that. Europe is the power as a powerhouse. I love that. Let's just have that as as the as a phrase. And I wanna I you know, we can't we can't do uh
42:42Unidentified speaker (UNKNOWN): you know,
42:43Unidentified speaker (speaker_0): an MA investment round table without talking about AI and you know, Sabina mentioned earlier on, it's obviously come up i i in terms of Sammy's uh conversation in you know within their portfolio as well. James, I imagine this has potentially caused the most uncertainty in some of the deal flow you've seen this year. Obviously, some of the things we've talked about, the administration, policy changes, even the FDA. There's been so many other things, but particularly for I imagine people people-based based businesses. businesses, services, consulting-based businesses, and potentially even manufacturing businesses. How how are you guys how are you advising clients to think about AI, maybe on the buy side and the sell side, in terms of, you know, are they are people underwriting AI? Are they just are they, you know, kind of skeptical of it and kind of discounting on deals because they think it's going to be a negative impact? I appreciate it's different. for for different types of deals, but you know, you've had the probably the broadest view on this this year. So I'd love for you to share how that's impacted kind of the deal flow across the m market.
43:51Unidentified speaker (speaker_2): Yeah, and I think that's the piece is that there is very much a distinct heat map in people people-based, based, project project-based based companies serving pharma. farmer. Some we've seen being much more susceptible to tools and technology. Really put a lot of pressure on pricing and how some services are able to be done. Others, I mean, there's some very strategic consultancies out there which run what you might think is a very traditional model of having people who've been around a sector the for a long time advising pharma farmer on uh their global strategy if it's for manufacturing. clinical, commercial, medical, market access. And we're seeing uh, if anything, heightened demand for those businesses versus others. Um there's been certainly a a lot of energy that a lot of um
44:39Unidentified speaker (UNKNOWN): uh
44:40Unidentified speaker (speaker_2): deals have been done in that sector. And yeah, there's a question there of
44:45Unidentified speaker (UNKNOWN): uh you
44:46Unidentified speaker (speaker_2): know how how at some point, you know, does all that knowledge with individuals eventually fit find its way into some huge data set um and become and and that data then is held at at an institutional level, and that is the knowledge because at the moment it's still held with people, um, and people and other buyers, strategic and private equity, are paying up for it. Um so yeah, very much a heat map, but for those um very strategic commercial consultants with we're still yeah, they're in high demand as of today.
45:18Unidentified speaker (speaker_0): Super interesting. And Sabina and Sami, I'm gonna come to you guys on the AI piece. When when you're assessing potential acquisitions now, I'm curious to understand like how big is the AI component of those. You know, I remember when I did my deal there was different levels of uh, you know, there was tax and there was finance and there was commercial diligence. And I imagine now an AI component will come into all of that. So uh maybe Sabine, I'll start with you on how you're when you're looking specifically at new assets. I'm not gonna necessarily focus on your existing stuff, but when you're looking at potentially new deals, how big is the the AI upside or d or downside risk with what you're looking to buy?
45:59Unidentified speaker (speaker_3): So today, um I think business. businesses that we're we're currently looking at, I think obviously if there's potentially significant AI downside that we can't quantificate, um, we we wouldn't look at it, right? And I think that's that's definitely there's a few, you know, pockets out there I think that are probably more more exposed than others. And it's just so so tough to underwrite because it's moving so quickly. and it you might have a good handle on things today, but in five years' time when you look to exit the business, you know, the backdrop could be completely different. And so I think that's that's quite difficult. I think in terms of those that are a bit more AI resilient, um, but might be using it for say, you know, their their operational workflows and not necessarily the core science, um, we're definitely not underwriting any type of AI related upside. Again, you know, hopefully that that comes through throughout the hold period, but we're we're pretty kind of conservative when thinking about the the outward model. And I think there's a lot of things that, you know, often get overlooked, right? Or we're still figuring out. You might be able to save a lot of time. Um You could save head headcount, but what's the what's the computational cost? How is that going to evolve
47:19over time? Um and equally, if this is something you're doing, you know, billing on an hourly basis, but you're delivering it in a few hours, um, does that automatically go to earnings or how are you pricing that? How is your customer looking to pay um for that project now? So there's a lot of things I think that are
47:38Unidentified speaker (UNKNOWN): still
47:39Unidentified speaker (speaker_3): large question marks. And so that's why we're we're looking at assets and companies that have less of that risk today with potential upsides in the future.
47:48Unidentified speaker (speaker_0): And Sami,
47:50Unidentified speaker (UNKNOWN): it
47:50Unidentified speaker (speaker_0): was interesting to get Sabina's view on that in terms of they're pretty conservative about AI upside and rightly so quite skeptical of anyone presenting that. I have a feeling you might be different. I don't know. Maybe you guys are looking at this differently, but this kind of entrepreneurial, kind of slightly riskier, I don't mean that in a negative way, just by virtue of being uh kind of doing kind of founder director institution deals and being earlier on. How do you how are you guys viewing the AI piece?
48:18Unidentified speaker (speaker_1): Yeah, usually I'll have my agent talk to their agents and then and then
48:22Unidentified speaker (UNKNOWN): and
48:22Unidentified speaker (speaker_1): then we do a debrief at the end of the diligence. No, the um
48:26Unidentified speaker (UNKNOWN): I
48:26Unidentified speaker (speaker_1): think we have to separate it because we invest in both software as well as services. On the software side, I think what's changed is that we have flipped the burden of proof when it comes to AI. And so historically, we might have looked at a business and asked, How can how can other technology, it wasn't always AI, right? But how could other technology potentially disrupt this business over time? Today, when we look at a software business, we're almost approaching it with an assumption that it will be disrupted. And then we have to prove in our diligence process why it won't be disrupted. And so that's almost how that burden has changed on the software side. On the services side, I think. similar to what Sabina mentioned, you know, we're looking at AI as an opportunity to increase efficiency of our businesses. And it's always a part of the diligence process around how can we how can we enable our companies with technology? Um, and and and that's an area that as a
49:36board we're always focused on. But we're not looking at that as like the needle mover on how you actually increase the value of the of the company over time. That's almost like a it's something that has to happen regardless in today's world.
49:51Unidentified speaker (speaker_0): All right. I want to move on. We only have a few minutes left and I wanted to do a bit of a lightning round, guys. And these are very, very general lightning round questions. Uh And I appreciate you probably don't want to uh kind of give the game away or so to speak and just kind of put yourself out there. But come on, have some fun. I'm gonna give you quick questions, guys. You can all come off mute and uh we'll go in order of Sabina, James, and Sammy for each of these as just just to give our listeners There's a kind of quick pulse check on what to expect in the future. Just a very quick answer. from each of you before we finish off with our final question. All right, first question valuations up or down in the next 12 months, Sabina?
50:34Unidentified speaker (speaker_3): Up.
50:34Unidentified speaker (speaker_0): James.
50:35Unidentified speaker (speaker_2): Also up.
50:36Unidentified speaker (speaker_0): Sami.
50:37Unidentified speaker (speaker_1): Up.
50:38Unidentified speaker (speaker_0): Okay, what a start. Three for three. Okay. More platform deals or more more boltons? Sabina?
50:45Unidentified speaker (speaker_3): Platform.
50:46Unidentified speaker (speaker_0): James.
50:46Unidentified speaker (speaker_2): I think boltons.
50:48Unidentified speaker (speaker_0): Ooh, Sammy.
50:49Unidentified speaker (speaker_1): All right. Boltons.
50:51Unidentified speaker (speaker_0): Boltons. Well, very good. You're two to one on that one, but I love the I I don't want you to agree on everyone, guys, so that's perfect. Um more US manufacturing or more Asia diversification, Sabina.
51:03Unidentified speaker (speaker_3): I'm gonna go with Asia.
51:05Unidentified speaker (speaker_0): Jims.
51:06Unidentified speaker (speaker_2): Uh I think it will be US, but I think long term Asia is the way.
51:10Unidentified speaker (speaker_0): Okay, Sammy.
51:11Unidentified speaker (speaker_1): US.
51:11Unidentified speaker (speaker_0): You said like a true American.
51:13Unidentified speaker (UNKNOWN): You
51:13Unidentified speaker (speaker_3): would obviously say that.
51:15Unidentified speaker (speaker_1): Said like someone from Ohio.
51:17Unidentified speaker (speaker_3): Yeah.
51:18Unidentified speaker (speaker_0): You just know Sammy is uh waving his US flag as he said that answer. Okay. Sabina, most attractive pharma services subsector or segment for 2027.
51:31Unidentified speaker (speaker_3): I'm gonna have to throw it out there for Sammy's Sami's benefit, but it's definitely peptides.
51:35Unidentified speaker (speaker_0): Okay, okay. James.
51:38Unidentified speaker (UNKNOWN): Is
51:38Unidentified speaker (speaker_2): personally or professionally are we using these peptides?
51:41Unidentified speaker (UNKNOWN): Exactly.
51:43Unidentified speaker (speaker_0): Encourage our listeners to go look at Sami's beautiful complexion and face like that. So James.
51:49Unidentified speaker (speaker_2): Um accelerating clinical development. So much to do there.
51:54Unidentified speaker (speaker_0): Okay. Sami.
51:56Unidentified speaker (speaker_1): Manufacturing enabling technologies and services. Anything around automation, validation, um AI in the manufacturing setting.
52:06Unidentified speaker (speaker_0): Alright, final one.
52:09Unidentified speaker (UNKNOWN): One
52:09Unidentified speaker (speaker_0): thing investors are underestimating right now, Sabina.
52:13Unidentified speaker (speaker_3): AI.
52:14Unidentified speaker (speaker_0): Jims.
52:16Unidentified speaker (speaker_2): I think it's still going to be the lack of A-star top-tier to companies for the next twelve months.
52:24Unidentified speaker (speaker_0): Sami.
52:25Unidentified speaker (speaker_1): How long it's gonna take for all these manufacturing announcements to actually translate into capacity.
52:31Unidentified speaker (speaker_0): Great, great one. Okay, we've got one minute left and I'm gonna finish with just a final comment on the the future and and heading into twenty twenty seven. So maybe give us a sense of your posit you know how how optimistic you are, how pessimistic you are, kind of on the fence you are, just in one sentence. So I'm gonna going to start with you, Sami, Sammy, first.
52:51Unidentified speaker (speaker_1): Um, I am I'm excited. I think coming out of CPHI a few weeks ago, I think there's real momentum we're seeing in our portfolio in terms of bookings, revenue growth, pipeline growth.
53:02Unidentified speaker (UNKNOWN): Um,
53:03Unidentified speaker (speaker_1): biotech funding's up, MA is up. Um, so I'm excited.
53:07Unidentified speaker (speaker_0): Jims.
53:08Unidentified speaker (UNKNOWN): I'm
53:08Unidentified speaker (speaker_2): gonna end this podcast the same way that I started being an optimist. Um I think technology. technology's really uh accelerated a lot of business models and a lot of innovation. It's really catalyzed a lot of that in our sector. And I think there's a lot to go for in uh in pharma services.
53:24Unidentified speaker (speaker_0): Sabina.
53:25Unidentified speaker (speaker_3): Agreed. Let's let's all be positive. I think it's been uh a rough few years. We're seeing some green shoots, um, a lot of exciting tech coming through. And I think twenty twenty seven is gonna be a really exciting rebound year. So let's see what happens.
53:41Unidentified speaker (speaker_0): Well, let's go. Love that. Great positive oh, sorry, uh you know optimism from our uh guests. Very positive about the future. Um what a great episode, guys. Thank you, Sammy, James, Sabina, three people I admire very much, consider friends for making the time and being guests on Molecule to Market. Thank you, guys.
54:00Unidentified speaker (speaker_1): Thank you.
54:02Unidentified speaker (UNKNOWN): Thank
54:02Unidentified speaker (speaker_2): you. for having us.
54:03Unidentified speaker (speaker_0): This episode is brought to you by Bora Pharmaceuticals. I've got a real soft spot for Bora. I first met Bobby Sheng, the CEO, back in 2017, and it's been amazing to watch the business grow and expand to become truly top tier global CDMO. Bobby was in fact one of our first ever guests on Molecule to Market. A great, great guy. Bora now supports many of the biggest. pharma companies across the globe. Bora's become known as the CDMO that brings a genuine partnership to clients, shown through their shared risk promise, their white glove service, and their peerless on-time infull delivery record. If you want to feel more confident about your CDMO, then I suggest you head to BoraCDMO.com. And I just want to say a special thanks to the team at League. Lead Candidate that support Monocule to Market. They really are the go-to talent partner for the pharma and biopharma outsourcing space. I should know because I helped co-found that business and they are doing amazing things for CROs
55:03and CDMOs in the sector. So for any talent needs, give the guys a shout. And there you have it, ladies and gents. That was the Pharma Services MA Quarter Four 2026 twenty twenty-six roundtable here. on Molecule to Market. Wow, so much to unpack in that episode today. I suspect you will go back and rewind and skip things and make lots of notes and share them with your colleagues. Huge, huge thanks to my guests uh today. Sammy Hower, who is uh a great guy, first and foremost, and co-founder at New Vale Capital. Sabina, Wimer Stores, who is principal at GHO Capital Partners, and Super Mum, as described in her biog. And last but certainly not least, James West, who is managing director, head of Europe at Bourne Partners, and an all-round great guy. Okay, I'm gonna try and pull a few things that really got my attention today. Um, first and foremost, good on them for showing some humility about the things that they thought were going to happen in the sector and you know didn't quite happen in the way they expected. But nevertheless, I think there was some positivity in there with respect to a recovering market and you know biotech funding coming back with a vengeance, albeit to James's point, taking a bit of time for that to flow into our space. Um
56:23and on the valuations and processes piece, I mean. so much to unpack there around buyers being much more cautious, diligence being much more kind of thorough than usual, pausing the processes, uh kind of a friction between valuations and bids, and also, as James talked about, a kind of creative way to do deals. I suppose Sammy's point around premium businesses and good businesses get premium valuations, uh, certainly certainly uh is fundamental to the whole thing. And, you know, good businesses get investment. It's is simple as that. And uh there were some you know interesting segments that James and Sabina mentioned, but I think there was definitely a sense from Sammy of not being fooled by the tailwinds and trends that are just fad. So I thought that was was super interesting. Uh fair play to the guys also were for talking about Tariffs Tariff Resuring and the in AI, they're not easy topics. to necessarily talk, but so much insight from the guys today. Uh and I suppose last but not least, a great kind of lightning round to finish today's podcast. And yeah, some commonality in what terms of what the guys say, but actually some some different views as well, which is what our podcast is all about. Really, really terrific show. I'm just sad we had to press stop at the end because we were just in the flow. But these are three busy people. Um and uh yeah, with very, very important jobs in respectable organizations. And
57:43so they had to get on with their day. But a huge thanks again to the wonderful Sammy, Sabina, and James for coming on the show. I owe you guys a drink at some point in time. And to you, listener, thank you so much for listening. I hope you enjoyed today's show. If you did, why not? Just go on onto to your podcast platform and of choice, leaving it a little clean waiting. I would say five stars is probably about right. And then maybe a little comment and even better, share it with a colleague. And if you really want to make my day, then subscribe to our newsletter because I'm going to be sending loads of good information about the market and things we've le learned from over six and a half years on the podcast Podcasts through the newsletter. That's going to be the source of a lot of good content in the next year ahead. But if you have a request for what you want to see more of or less of or new stuff on the podcast, then I'm open to ideas because we're looking to do a huge refresh and revamp of Molecule to Market in 2027. And I'd love you to be on that journey with us. As always, thanks to my team, uh Tony and Susan for making this possible and putting our podcast episode together so it comes to your ears in a nice, timely and quality fashion. I will see you guys very soon. Hi again. Thanks for tuning in to today's show. Really hope you enjoyed the episode.
59:02For more shows, have a look on Spotify, Apple or Amazon, wherever you like to listen. And do make sure that you subscribe so the next episode comes direct to you. your device automatically. And please get in touch via our website at Molecule to Market Pod or via LinkedIn or Twitter. We love to hear from you. So if you have a guest that you want to suggest or someone in your organization that you think would make a great guest on Molecule to Market, then please let us know. We'll see you very soon.